Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?

Zinger Key Points

Gilead Sciences Inc GILD announced an agreement with Compugen Ltd CGEN to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 drug candidate.

COM503 is a potential first-in-class, high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth.

Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503. After that, Gilead will have the sole right to develop and commercialize COM503.

Gilead will make Compugen an upfront payment of $60 million and $30 million in a near-term milestone payment subject to IND clearance of COM503 expected in 2024. 

Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory, and commercial milestone payments, with a total deal value of $848 million. 

Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.

This transaction with Compugen is expected to reduce Gilead's GAAP and non-GAAP 2023 EPS by approximately $0.03-$0.05.

Concurrently, Compugen also said it will be eligible to receive a milestone payment of $10 million from AstraZeneca Plc AZN when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig derived from Compugen's clinical-stage anti-TIGIT antibody, COM902

The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects with biliary tract cancer.

Price Action: CGEN shares are up 152.10% at $1.84 on the last check Tuesday.

CGEN Logo
CGENCompugen Ltd
$1.59-4.22%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
42.22
Growth
Not Available
Quality
Not Available
Value
57.95
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...